Dyne Therapeutics 40% Rally Faces Fund Selloff Questions
A dramatic 40% jump for Dyne Therapeutics has investors watching closely as a biotech-focused fund disclosed a sizabl...
Explore the question of which is better for daily expenses: cash back or points. Make informed choices to maximize your rewards potential.
27,346 articlesA dramatic 40% jump for Dyne Therapeutics has investors watching closely as a biotech-focused fund disclosed a sizabl...
Franklin Templeton is pursuing two ETFs that redirect dividend payments into Bitcoin exposure, a move that could redr...
Big-name bets via 13F filings often reveal more about risk management than marketing hype. This quarter, billionaire ...
As workers reassess early retirement, a dividend-heavy portfolio could substitute lost full-time income. This piece b...
NVIDIA guided higher-than-expected revenue for the coming quarter, but investors greeted the news with a muted respon...
Investors chasing steady monthly income via QYLD face a trade-off: the cost of covered-call income can outpace Nasdaq...
A prominent billionaire asserts the market is underestimating how far the Federal Reserve may go with rate cuts. This...
As market chatter heats up in 2026, investors are watching whether GE Vernova, MercadoLibre, or NVR will join the gro...
Comcast announced a UK broadcaster acquisition just days after revealing NBCUniversal’s spin-off plan, signaling a bo...
Insider moves can tell us a lot about a stock’s near-term path. When Intuitive Machines’ CEO disclosed a $1.39 millio...
Drones and government funding chatter are reshaping investor sentiment. Ondas is at the center of the action, with ot...
Fermi America slumped 11.5% as it unveiled a $375 million convertible note offering and reported a Q1 with zero reven...